JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

JNJ

230.71

+2.74%↑

ABT

92.25

+0.67%↑

MDT

83.66

+0.75%↑

113.29

-6.55%↓

VEEV

155.04

-4.54%↓

Home・Akcijų sąrašas・Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings Inc

Atidarymo kaina

SektoriusSveikatos priežiūra

32.09 0.79

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

31.53

Max

32.62

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-28M 22M
Pardavimai	4.3M 244M
P/E Sektoriaus vid.	10.897 60.328
Pelno marža	9.224
Darbuotojai	293
EBITDA	-22M 52M

Rekomendacijos
By TipRanks
Rekomendacijos	Pirkti
12 mėnesių prognozė	+34.16% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-05

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	161M 1.7B
Ankstesnė atidarymo kaina	31.3
Ankstesnė uždarymo kaina	32.09

Naujienos nuotaikos

By Acuity

34%

66%

132 / 348 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Weak Bullish Evidence

29.8 / N/A Palaikymas ir pasipriešinimas

Harmony Biosciences Holdings Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-04-23 00:00; UTC

Svarbiausios naujienos

Australian Flash PMI Bounce in April Conceals Deeper Worries

2026-04-22 23:33; UTC

Uždarbis

SK Hynix Posts Record Quarterly Results Amid AI Boom

2026-04-22 22:40; UTC

Uždarbis

Correction to ServiceNow Posts 22% 1Q Revenue Growth Article

2026-04-22 22:10; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4 Billion Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:11; UTC

Uždarbis

ServiceNow Posts 22% 1Q Revenue Growth, But Says Armis Deal Will Weigh on Margins

2026-04-22 21:01; UTC

Uždarbis

IBM Posts Higher 1Q Sales, Buoyed by AI -- Update

2026-04-22 23:46; UTC

Rinkos pokalbiai

Global Equities Roundup: Market Talk

2026-04-22 23:46; UTC

Rinkos pokalbiai

Nikkei May Remain Rangebound; Middle East Conflict in Focus -- Market Talk

2026-04-22 23:34; UTC

Rinkos pokalbiai

Svarbiausios naujienos

Gold Falls as U.S.-Iran Cease-Fire Keeps Inflation Concerns High -- Market Talk

2026-04-22 23:16; UTC

Uždarbis

SK Hynix: Quarterly Revenue, Profits at All-Time High in 1Q

2026-04-22 23:15; UTC

Uždarbis

SK Hynix: Operating Profit Margin Reached Record 72% in 1Q

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net Profit Beat FactSet-Compiled Consensus

2026-04-22 22:54; UTC

Uždarbis

SK Hynix 1Q Net KRW40.346T Vs. Net KRW8.108T >000660.SE

2026-04-22 22:52; UTC

Uždarbis

SK Hynix 1Q Oper Pft KRW37.610T Vs. Pft KRW7.441T >000660.SE

2026-04-22 22:51; UTC

Uždarbis

SK Hynix 1Q Rev KRW52.576T Vs. KRW17.639T >000660.SE

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: Delivery Risk, Input Cost Pressure Could Rise Quickly If Situation Deteriorates

2026-04-22 22:31; UTC

Uždarbis

Sandfire CEO: First, Second Order Impacts of Middle East Conflict Remain Hard to Predict

2026-04-22 22:30; UTC

Uždarbis

Sandfire CEO: Middle East Conflict Creates Significant Risk in Global Supply Chains

2026-04-22 22:30; UTC

Uždarbis

Sandfire: FY26 Underlying Operating Unit Costs Expected to 'Materially Aligned' With Guidance

2026-04-22 22:29; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Underlying Ebitda $220 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Unaudited Sales Revenue $408 Million

2026-04-22 22:28; UTC

Uždarbis

Sandfire Resources 3Q Motheo Underlying Operating Unit Cost $44/Ton Ore Processed

2026-04-22 22:27; UTC

Uždarbis

Sandfire Resources 3Q Matsa Underlying Operating Unit Cost $95/Ton Ore Processed

2026-04-22 22:06; UTC

Rinkos pokalbiai

Uždarbis

Tesla Paid Robotaxi Miles Nearly Doubled Quarter-Over-Quarter -- Market Talk

2026-04-22 21:55; UTC

Įsigijimai, susijungimai, perėmimai

ServiceNow Says $4B Term Loan Credit Deal Will Help Finance Armis Security Deal

2026-04-22 21:47; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:37; UTC

Uždarbis

Texas Instruments Reports Solid Earnings. The Stock Is Up. -- Barrons.com

2026-04-22 21:34; UTC

Uždarbis

Tesla Surprises Wall Street With Better Profits, $1.4 Billion in Free Cash Flow -- 3rd Update

2026-04-22 21:29; UTC

Uždarbis

Lam Research Stock Jumps on Strong Earnings -- Barrons.com

2026-04-22 21:20; UTC

Rinkos pokalbiai

Uždarbis

Tesla Expands Manufacturing to Chips -- Market Talk

Akcijų palyginimas

Kainos pokytis

Harmony Biosciences Holdings Inc Prognozė

Kainos tikslas

By TipRanks

34.16% į viršų

12 mėnesių prognozė

Vidutinis 42.89 USD 34.16%

Aukščiausias 72 USD

Žemiausias 25 USD

Remiantis 9 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Harmony Biosciences Holdings Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

9 ratings

Pirkti

Laikyti

Parduoti

Remiantis 9 analitikų, pateikusių Harmony Biosciences Holdings Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

29.8 / N/APalaikymas ir pasipriešinimas

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Rinkos nuotaikos

By Acuity

132 / 348 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Harmony Biosciences Holdings Inc

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.